# Alto Neuroscience, Inc.: overview ANRO · NYSE · CIK 1999480 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/anro.md) · [Financials](/companies/anro/financials.md) · [Filings](/companies/anro/filings.md) · [Insiders](/companies/anro/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.62)](/filings/0001999480-25-000090.md) | not reported | [(0.56)](/filings/0001999480-26-000012.md) | [(0.65)](/filings/0001999480-26-000023.md) | [(0.52)](/filings/0001999480-25-000090.md) | not reported | [(0.80)](/filings/0001999480-26-000012.md) | [(0.65)](/filings/0001999480-26-000023.md) | | Free cash flow | $m | [(12.7) d](/filings/0001999480-25-000090.md) | [(13.5) d](/filings/0001999480-26-000002.md) | [(16.6)](/filings/0001999480-26-000012.md) | [(13.8) d](/filings/0001999480-26-000023.md) | [(9.9) d](/filings/0001999480-25-000090.md) | [(11.5) d](/filings/0001999480-26-000002.md) | [(27.6)](/filings/0001999480-26-000012.md) | [(19.8) d](/filings/0001999480-26-000023.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(9.73)](/filings/0001999480-25-000025.md) | [(2.50)](/filings/0001999480-26-000002.md) | [(2.19)](/filings/0001999480-26-000002.md) | | Free cash flow | $m | [(33.9)](/filings/0001999480-25-000025.md) | [(49.5)](/filings/0001999480-26-000002.md) | [(51.8)](/filings/0001999480-26-000002.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anro/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Alpha Wave Global, LP](/funds/1558858.md) | 2026-06-30 | $97.8m | 3,707,757 | | Unchanged | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $71.9m | 2,723,196 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $56.0m | 2,121,009 | | Added +1,454,821 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $42.5m | 1,609,893 | | Reduced −400,000 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $42.2m | 1,600,000 | | Added +1,215,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $36.7m | 1,389,477 | | Added +182,452 | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $35.7m | 1,353,047 | | Added +27,837 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $31.9m | 1,208,858 | | Added +173,307 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $26.7m | 1,013,307 | | Reduced −88,567 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $22.8m | 864,000 | | Reduced −48,000 | ## Recent filings [All 192 filings](/companies/anro/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-27 | 17:18 ET | [8-K](/filings/0001999480-26-000024.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001999480-26-000024 | | 2026-08-12 | 16:27 ET | [10-Q](/filings/0001999480-26-000023.md) | Quarterly report, period 2026-06-30 | 0001999480-26-000023 | | 2026-08-12 | 16:14 ET | [8-K](/filings/0001999480-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001999480-26-000022 | | 2026-07-14 | 06:04 ET | [8-K](/filings/0001104659-26-083274.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-083274 | | 2026-07-13 | 07:39 ET | [8-K](/filings/0001104659-26-082875.md) | 2.02 Results of operations; 8.01 Other events | 0001104659-26-082875 | | 2026-05-28 | 08:18 ET | [8-K](/filings/0001999480-26-000016.md) | 5.02 Departure or appointment of officers or directors | 0001999480-26-000016 | | 2026-05-13 | 16:21 ET | [8-K](/filings/0001999480-26-000014.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001999480-26-000014 | | 2026-05-13 | 07:30 ET | [10-Q](/filings/0001999480-26-000012.md) | Quarterly report, period 2026-03-31 | 0001999480-26-000012 | | 2026-05-13 | 07:04 ET | [8-K](/filings/0001999480-26-000011.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001999480-26-000011 | | 2026-04-01 | 16:55 ET | [8-K](/filings/0001104659-26-038593.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-038593 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001999480-26-000002.md), filed Mar 16, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1999480 - Tickers: ANRO - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:02 ET. No prices; not investment advice.